Pivotal Research Maintains Hold on Spotify Technology, Raises Price Target to $130

Pivotal Research analyst Jeffrey Wlodarczak maintains Spotify Technology (NYSE:SPOT) with a Hold and raises the price target from $100 to $130.

byBenzinga Newsdesk

February 1, 2023

1 minute read

Pivotal Research analyst Jeffrey Wlodarczak maintains Spotify Technology (NYSE:SPOT) with a Hold and raises the price target from $100 to $130.

Needham Upgrades BioCryst Pharmaceuticals to Buy, Maintains $14 Price Target

By Benzinga Newsdesk

Today, 7:06 AM

Needham analyst Serge Belanger upgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) from Hold to Buy and maintains $14 price target.

BCRX

Here’s Why Pete Najarian Says Disney Stock Can ‘Go A Lot Higher’

By Adam Eckert

Today, 7:06 AM

Walt Disney Co (NYSE: DIS) was featured as the call of the day Thursday on CNBC's "Fast Money Halftime Report."

DIS

News

Return On Capital Employed Overview: Eversource Energy

By Benzinga Insights

Today, 7:06 AM

Looking at Q1, Eversource Energy (NYSE:ES) earned $585.57 million, a 28.77% increase from the preceding quarter. Eversource Energy also posted a total of $2.83 billion in sales, a 26.5% increase since Q4. Eversource Energy earned $454.73 million, and sales totaled $2.23 billion in Q4.

News

AstraZeneca Announced Vaxzevria Shown in Expert Review to Provide Equally Effective Protection Against COVID-19 hospitalization and Death as mRNA Vaccines

By Charles Gross

Today, 7:06 AM

An expert review of data from 79 real-world studies showed that AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]) and the available mRNA COVID-19 vaccines provide equally effective protection against hospitalisation and death from COVID-19 following two doses.1

AZN

Pivotal Research Maintains Hold on Spotify Technology, Raises Price Target to $130

Related Posts

Needham Upgrades BioCryst Pharmaceuticals to Buy, Maintains $14 Price Target

Here’s Why Pete Najarian Says Disney Stock Can ‘Go A Lot Higher’

Return On Capital Employed Overview: Eversource Energy

AstraZeneca Announced Vaxzevria Shown in Expert Review to Provide Equally Effective Protection Against COVID-19 hospitalization and Death as mRNA Vaccines